Scotland backs AZ’s Lynparza for first-line ovarian cancer maintenanceThe Scottish Medicines Consortium (SMC) has backed routine funding of AstraZeneca and MSD’s Lynparza as a maintenance treatment Share XScotland backs AZ’s Lynparza for first-line ovarian cancer maintenancehttps://pharmaphorum.com/news/scotland-backs-azs-lynparza-for-first-line-ovarian-cancer-maintenance/
ViiV presses go on FDA filing for first-in-class HIV drug fostemsavirViiV Healthcare has fulfilled its pledge of submitting its new HIV drug fostemsavir for approval before year end, Share XViiV presses go on FDA filing for first-in-class HIV drug fostemsavirhttps://pharmaphorum.com/news/viiv-presses-go-on-fda-filing-for-first-in-class-hiv-drug-fostemsavir/
Amgen strikes outcomes-based payment plan for Enbrel with AbarcaPharmacy benefit manager Abarca has announced a US reimbursement contract with Amgen for its Enbrel (etanercept) inflammatory diseases Share XAmgen strikes outcomes-based payment plan for Enbrel with Abarcahttps://pharmaphorum.com/news/amgen-strikes-outcomes-based-payment-plan-for-enbrel-with-abarca/
US eyes faster launch for biosimilars in North American trade pact; reportsBiosimilars could be brought to market much quicker in North America if a Trump administration proposal makes it Share XUS eyes faster launch for biosimilars in North American trade pact; reportshttps://pharmaphorum.com/news/us-eyes-shorter-exclusivity-for-biologic-drugs-in-trade-pact-report/
Senate committee backs Hahn as new FDA CommissionerPresident Trump’s pick for the new FDA Commissioner – Stephen Hahn – has picked up the endorsement he Share XSenate committee backs Hahn as new FDA Commissionerhttps://pharmaphorum.com/news/senate-committee-backs-hahn-as-new-fda-commissioner/
FDA sets January action date for Keytruda in early bladder cancerMerck & Co/MSD has filed for approval of its PD-1 inhibitor Keytruda in a hard-to-treat form of bladder Share XFDA sets January action date for Keytruda in early bladder cancerhttps://pharmaphorum.com/news/fda-sets-january-action-date-for-keytruda-in-early-bladder-cancer/
Mylan and Biocon launch Herceptin biosimilar in USMylan and Biocon have launched their Herceptin biosimilar Ogivri in the US, the second challenger to Roche’s breast Share XMylan and Biocon launch Herceptin biosimilar in UShttps://pharmaphorum.com/news/mylan-and-biocon-launch-herceptin-biosimilar-in-us/
ABPI looks internally for new CEO, naming Richard TorbettThe new chief executive of the Association of the British Pharmaceutical Industry (ABPI) will be Dr Richard Torbett Share XABPI looks internally for new CEO, naming Richard Torbetthttps://pharmaphorum.com/news/abpi-looks-internally-for-new-ceo-naming-richard-torbett/
FDA guidance finally opens door for insulin biosimilarsNew draft guidance from the FDA has opened the door for the development of insulin biosimilars, potentially allowing Share XFDA guidance finally opens door for insulin biosimilarshttps://pharmaphorum.com/news/fda-guidance-finally-opens-door-for-insulin-biosimilars/
NICE backs Lynparza across the board for BRCA+ovarian cancerAstraZeneca and MSD’s Lynparza has become the first PARP inhibitor to be recommended for all lines of maintenance Share XNICE backs Lynparza across the board for BRCA+ovarian cancerhttps://pharmaphorum.com/news/nice-backs-lynparza-across-the-board-for-brca-ovarian-cancer/
ICER says ‘marginal’ benefits for AbbVie’s new RA drugAbbVie’s Rinvoq rheumatoid arthritis drug is an important part of the company’s strategy to replace lost sales as Share XICER says ‘marginal’ benefits for AbbVie’s new RA drughttps://pharmaphorum.com/news/icer-says-marginal-benefits-for-abbvies-new-ra-drug/
Drugs firms make massive discounts to get reimbursement in ChinaRoche and Novartis are among the pharmaceuticals companies who have agreed to cut prices of some of their Share XDrugs firms make massive discounts to get reimbursement in Chinahttps://pharmaphorum.com/news/drugs-firms-make-massive-discounts-to-get-reimbursement-in-china/
NICE backs Ibrance for breast cancer via Cancer Drugs FundPfizer’s Ibrance has been approved for use by the NHS in England as a second-line treatment for advanced Share XNICE backs Ibrance for breast cancer via Cancer Drugs Fundhttps://pharmaphorum.com/news/nice-backs-ibrance-for-breast-cancer-via-cancer-drugs-fund/
Trump’s reps ‘pushed hard’ for UK drug price reforms, leaked documents showRepresentatives of the Trump administration have “pushed hard” for pro-US drug pricing reforms in free trade negotiations with Share XTrump’s reps ‘pushed hard’ for UK drug price reforms, leaked documents showhttps://pharmaphorum.com/news/trump-administration-pushed-hard-for/
NHS patients to get easier access to MS pill after NICE rethinkPatients in England are to get easier access to Merck KGaA’s multiple sclerosis drug Mavenclad after NICE dropped Share XNHS patients to get easier access to MS pill after NICE rethinkhttps://pharmaphorum.com/news/nhs-patients-to-get-easier-access-to-ms-pill-after-nice-rethink/
Chasing Mylan, Hikma tries again with rejected generic Advair in USUK-listed Hikma Pharma has filed a response to the FDA that it hopes will clear the way for Share XChasing Mylan, Hikma tries again with rejected generic Advair in UShttps://pharmaphorum.com/news/chasing-mylan-hikma-tries-again-with-rejected-generic-advair-in-us/
FDA rejects Adamis opioid overdose therapy Zimhi, hitting share priceShares in Adamis Pharmaceuticals have been poleaxed by an FDA decision to reject Zimhi, intended as a treatment Share XFDA rejects Adamis opioid overdose therapy Zimhi, hitting share pricehttps://pharmaphorum.com/news/fda-rejects-adamis-opioid-overdose-therapy-zimhi-hitting-share-price/
FDA cues up May verdict for Roche’s SMA challenger risdiplamThe FDA has started a priority review of Roche’s spinal muscular atrophy (SMA) candidate risdiplam, with a decision Share XFDA cues up May verdict for Roche’s SMA challenger risdiplamhttps://pharmaphorum.com/news/fda-cues-up-may-verdict-for-roches-sma-challenger-risdiplam/
